How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?

AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer immunology medicines, Rinvoq and Skyrizi, not only mitigated the impact of Humira’s continued erosion but also reaffirmed their role as growth drivers for AbbVie.Skyrizi...